OPTIMIZING ADJUNCTIVE IOP-LOWERING THERAPY: Rationale and Benefits for Prescribing Istalol®

July 15, 2008

Ideally, control of elevated IOP in patients with ocular hypertension or glaucoma might be achieved with monotherapy. However, published data indicate that treatment with a single modality is often not enough. In the Ocular Hypertension Treatment Study, which enrolled a generally healthy cohort and set a relatively modest therapeutic goal of a ?20% IOP reduction, 40% of patients needed 2 medications and 10% required 3 medications to reach this goal. These results are consistent with those in other publications and my clinical experience.